Solution Group

Equities

SOLUTN

MYQ0093OO003

Investment Holding Companies

End-of-day quote BURSA MALAYSIA 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
0.185 MYR 0.00% Intraday chart for Solution Group -2.63% -15.91%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Solution Group Berhad Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Solution Group Berhad Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Solution Group Berhad Appoints Wang, Hongyi as Executive Director CI
Solution Group Completes Private Placement MT
Solution Group Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Solution Group Berhad Announces Resignation of Lim Hai Guan as Executive Director CI
Solution Group Berhad Appoints Wong Yuen Hoe as Independent and Non Executive Director CI
Solution Group Berhad Announces Redesignation of Datuk Dr Syed Muhamad Bin Syed Abdul Kadir to Non Independent and Non Executive Chairman CI
Solution Group Berhad Announces Redesignation of SYED MUHAMAD BIN SYED ABDUL KADIR to Non Independent and Non Executive Member of Nomination and Remuneration Committee CI
Solution Group Berhad Appoints YVONNE LOW WIN KUM as Independent and Non Executive Member of Nomination and Remuneration Committee CI
Solution Group Berhad Announces Redesignation of Datuk Dr Syed Muhamad Bin Syed Abdul Kadir to Non Independent and Non Executive Member of Audit Committee CI
Solution Group Berhad Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Solution Group Berhad Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Solution Group Berhad Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Solution Group Berhad Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Solution Group Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Solution Group Berhad Appoints Miss Yvonne Low Win Kum as Independent and Non Executive Director CI
Solution Group Berhad Appoints Miss Yvonne Low Win Kum as Independent and Non Executive Member of Audit Committee CI
Solution Group Berhad Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Solution's Unit Inks MOU for Vaccine Development MT
Solution Biologics Sdn Bhd Signs Memorandum of Understanding with National Institutes of Biotechnology Malaysia and CanSino Biologics Inc CI
Solution Group Berhad First Interim Dividend Single Tier Dividend, Payment Date Is 23 March 2022 CI
Solution Group Berhad Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021 CI
Solution Group Unit Wins Good Manufacturing Practices Nod for COVID-19 Vaccine MT
Solution Group Grants 6 Million Share Options to Eligible Employees, Directors MT
Chart Solution Group
More charts
Solution Group Berhad is a Malaysia-based technology investment company. Its Engineering Equipment segment is engaged in designing and developing equipment and software for engineering education, research and technical and vocational education and training in chemical, mechanical and various others. Its Metal Fabrication and Assembly Works segment is engaged in the provision of fabrication for pressurized vessels, process skids assembly and various others. Its Industrial Automation and Plant Construction segment is engaged in the provision of industrial automation and system integration solutions. Its Green and Renewal Energy segment is involved in the promotion of business relating to green and renewal energy. Its Biopharmaceuticals & Biotechnology segment is engaged in sales and manufacture of medical, botanical products and various others. Its Industrial Lubricants segment is engaged in the production and distribution of industrial lubricants under SOLMAX brand and OEM brand.
More about the company
  1. Stock Market
  2. Equities
  3. SOLUTN Stock
  4. News Solution Group
  5. Solution's Unit Inks MOU for Vaccine Development